A Phase 1, Open Label, Study in Healthy Female Subjects to Describe GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue Following Single and Multiple Dosing of GSK1349572.
Phase of Trial: Phase I
Latest Information Update: 03 Jul 2013
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- 08 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Nov 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 01 Aug 2011 New trial record